The mechanisms of alloxan- and streptozotocin-induced diabetes

Alloxan and streptozotocin are toxic glucose analogues that preferentially accumulate in pancreatic beta cells via the GLUT2 glucose transporter. In the presence of intracellular thiols, especially glutathione, alloxan generates reactive oxygen species (ROS) in a cyclic redox reaction with its reduction product, dialuric acid. Autoxidation of dialuric acid generates superoxide radicals, hydrogen peroxide and, in a final iron-catalysed reaction step, hydroxyl radicals. These hydroxyl radicals are ultimately responsible for the death of the beta cells, which have a particularly low antioxidative defence capacity, and the ensuing state of insulin-dependent ‘alloxan diabetes’. As a thiol reagent, alloxan also selectively inhibits glucose-induced insulin secretion through its ability to inhibit the beta cell glucose sensor glucokinase. Following its uptake into the beta cells, streptozotocin is split into its glucose and methylnitrosourea moiety. Owing to its alkylating properties, the latter modifies biological macromolecules, fragments DNA and destroys the beta cells, causing a state of insulin-dependent diabetes. The targeting of mitochondrial DNA, thereby impairing the signalling function of beta cell mitochondrial metabolism, also explains how streptozotocin is able to inhibit glucose-induced insulin secretion.

[1]  E. Wilander,et al.  Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. , 1976, The Journal of endocrinology.

[2]  W. Malaisse,et al.  Long term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic islets. , 1992, Endocrinology.

[3]  S. Lenzen,et al.  Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme. , 1988, Molecular pharmacology.

[4]  J. Patterson,et al.  The Mechanism of Cysteine and Glutathione Protection Against Alloxan Diabetes. , 1948, Science.

[5]  A. P. Autor Pathology of oxygen , 1982 .

[6]  S. Marklund,et al.  Influence of trace metals on alloxan cytotoxicity in pancreatic islets , 1979, FEBS letters.

[7]  V. Devita,et al.  Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998) , 1974, Cancer.

[8]  O. Korsgren,et al.  Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations , 1988, Molecular and Cellular Endocrinology.

[9]  N. McLetchie,et al.  EXPERIMENTAL ALLOXAN DIABETES IN THE RAT , 1943 .

[10]  J. Logothetopoulos,et al.  Proinsulin biosynthesis by pancreatic islets of the rat and the study of alloxan cytotoxicity in vitro. , 1976, Biochimica et biophysica acta.

[11]  S. Lenzen,et al.  Relation between triketone structure, generation of reactive oxygen species, and selective toxicity of the diabetogenic agent alloxan. , 2008, Antioxidants & redox signaling.

[12]  H. Kolb,et al.  Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin , 1999, Nature Medicine.

[13]  S. Lenzen,et al.  Alloxan: history and mechanism of action , 1988, Diabetologia.

[14]  C. D. Barry,et al.  Molecular requirements for recognition at glucoreceptor for insulin release. , 1979, Molecular pharmacology.

[15]  H. Okamoto,et al.  Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. , 1982, The Journal of biological chemistry.

[16]  B. Lin,et al.  Interaction of Alloxan and Anomers of D-Glucose on Glucose-induced Insulin Secretion and Biosynthesis in Vitro , 1976, Diabetes.

[17]  R. Munday,et al.  Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan , 2002, Diabetologia.

[18]  M. Mcdaniel,et al.  Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. , 1993, Biochemical and biophysical research communications.

[19]  W. Malaisse,et al.  Defective catabolism of D-glucose and L-glutamine in mouse pancreatic islets maintained in culture after streptozotocin exposure. , 1988, Endocrinology.

[20]  T Szkudelski,et al.  The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. , 2001, Physiological research.

[21]  M. Glitzer,et al.  Light and Electron Microscopy of Lesions in Rats Rendered Diabetic with Streptozotocin , 1967, Diabetes.

[22]  I. Swenne,et al.  Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro , 1983, Diabetologia.

[23]  H. Hara,et al.  Parallel Inhibition of Islet Glucokinase and Glucose-Stimulated Insulin Secretion by Either Alloxan or Ninhydrin , 1986 .

[24]  J. Okuda,et al.  Inhibition of rat liver glucokinase by alloxan and ninhydrin. , 1986, Chemical & pharmaceutical bulletin.

[25]  H. Ebelt,et al.  ‘Classical’ and ‘new’ diabetogens—comparison of their effects on isolated rat pancreatic islets in vitro , 2000, Cellular and Molecular Life Sciences CMLS.

[26]  S. Lenzen,et al.  Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan , 2003, Diabetologia.

[27]  M. Welsh,et al.  Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of B-cells. , 1991, Biochemical pharmacology.

[28]  Konstantin Bloch,et al.  Streptozotocin and Alloxan-based Selection Improves Toxin Resistance of Insulin-Producing RINm Cells , 2000, International journal of experimental diabetes research.

[29]  S. Lenzen,et al.  Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[30]  W. Malaisse,et al.  Pancreatic uptake of [2-(14)C]alloxan. , 2001, International journal of molecular medicine.

[31]  J. E. Kudlow,et al.  The role of O-linked protein glycosylation in β-cell dysfunction (review) , 2002 .

[32]  S. Snyder,et al.  Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Patterson,et al.  Alloxan and dialuric acid; their stabilities and ultraviolet absorption spectra. , 1949, The Journal of biological chemistry.

[34]  L. Oberley Free radicals and diabetes. , 1988, Free radical biology & medicine.

[35]  M. Goldner,et al.  Acute Nature of Alloxan Damage.* , 1945 .

[36]  R. Munday,et al.  Comparative toxicity of alloxan, N-alkylalloxans and ninhydrin to isolated pancreatic islets in vitro. , 1997, The Journal of endocrinology.

[37]  G. Cohen,et al.  The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.

[38]  R. Heikkila,et al.  The prevention of alloxan-induced diabetes in mice by the iron-chelator detapac: Suggestion of a role for iron in the cytotoxic process , 1982, Experientia.

[39]  H. Ebelt,et al.  Scavenging effect of melatonin on hydroxyl radicals generated by alloxan , 2000, Journal of pineal research.

[40]  C. Newgard,et al.  STZ Transport and Cytotoxicity: Specific Enhancement in GLUT2-Expressing Cells , 1994, Diabetes.

[41]  S. Marklund,et al.  Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro. , 1979, The Biochemical journal.

[42]  Zhiyong Wang,et al.  GLUT2 in Pancreatic Islets: Crucial Target Molecule in Diabetes Induced With Multiple Low Doses of Streptozotocin in Mice , 1998, Diabetes.

[43]  N. J. Patton,et al.  Mechanisms of Nitrosourea-Induced β-Cell Damage: Alterations in DNA , 1986, Diabetes.

[44]  P. Schein,et al.  The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. , 1967, Cancer research.

[45]  C. D. Barry,et al.  Alloxan Stimulation and Inhibition of Insulin Release from Isolated Rat Islets of Langerhans , 1978, Diabetes.

[46]  P. Lacy,et al.  Alloxan uptake by isolated rat islets of Langerhans. , 1978, Endocrinology.

[47]  L. Borg Effects of alloxan on the islets of Langerhans: inhibition of leucine metabolism and insulin secretion. , 1981, Biochimica et biophysica acta.

[48]  A. Pegg,et al.  Alkylation of DNA in rat tissues following administration of streptozotocin. , 1981, Cancer research.

[49]  S. Lenzen,et al.  Importance of cysteine residues for the stability and catalytic activity of human pancreatic beta cell glucokinase. , 2000, Archives of biochemistry and biophysics.

[50]  R. Munday,et al.  Glutathione-mediated redox cycling of alloxan. Mechanisms of superoxide dismutase inhibition and of metal-catalyzed OH. formation. , 1989, Biochemical pharmacology.

[51]  L. Hammarström,et al.  On the accumulation of alloxan in the pancreatic β-cells , 1967, Diabetologia.

[52]  R. Weiss Streptozocin: a review of its pharmacology, efficacy, and toxicity. , 1982, Cancer treatment reports.

[53]  N. Rakieten,et al.  Studies on the diabetogenic action of streptozotocin (NSC-37917). , 1963, Cancer chemotherapy reports.

[54]  D. Pipeleers,et al.  Selective uptake of alloxan by pancreatic B-cells. , 1982, The Biochemical journal.

[55]  H. Sheehan,et al.  NECROSIS OF ISLETS OF LANGERHANS PRODUCED EXPERIMENTALLY , 1943 .

[56]  J. Cunningham,et al.  Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-releasing or O6-alkylating ability. , 1995, Biochemical pharmacology.

[57]  N. J. Patton,et al.  Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA. , 1986, Diabetes.

[58]  E. Wertheimer,et al.  Alloxan studies; the action of alloxan homologues and related compounds. , 1947, The Journal of biological chemistry.

[59]  R. Munday,et al.  Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin , 2000, Diabetologia.

[60]  I. Gelfand,et al.  Lessons from Animal Diabetes VI , 1996, Rev.Ser.Advs.Research Diab.Animals (Birkhäuser).

[61]  R. Munday,et al.  Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro. , 1999, Free radical biology & medicine.

[62]  S. J. Cooperstein,et al.  15 – Action of Toxic Drugs on Islet Cells , 1981 .

[63]  G. Bhattacharya,et al.  Reversal of the diabetogenic action of alloxan by sulfhydryl compounds. , 1952, Science.

[64]  R. Munday,et al.  Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. , 1991, Biochemical pharmacology.

[65]  M. Goldner,et al.  ALLOXAN DIABETES IN THE DOG1 , 1943 .

[66]  R. Munday,et al.  The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. , 1993, The Journal of endocrinology.

[67]  J. Liebig,et al.  Untersuchungen über die Natur der Harnsäure , 1838 .

[68]  C. Rerup Drugs producing diabetes through damage of the insulin secreting cells. , 1970, Pharmacological reviews.

[69]  R. Munday,et al.  Alloxan derivatives as a tool for the elucidation of the mechanism of the diabetogenic action of alloxan , 1996 .

[70]  R. Munday Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of "active oxygen" species. , 1988, Biochemical pharmacology.

[71]  C. Hellerström,et al.  Acute Effects of Alloxan on the Metabolism and Insulin Secretion of the Pancreatic B-Cell , 1973, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[72]  J. E. Kudlow,et al.  The role of O-linked protein glycosylation in beta-cell dysfunction. , 2002, International journal of molecular medicine.

[73]  P. Schein,et al.  Streptozotocin: depression of mouse liver pyridine nucleotides. , 1968, Cancer research.

[74]  S. Kawanishi,et al.  Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. , 1999, Biochemical pharmacology.

[75]  G. Cohen,et al.  Alloxan-induced diabetes-evidence for hydroxyl radical as a cytotoxic intermediate. , 1976, Biochemical pharmacology.

[76]  N. McLetchie Alloxan diabetes: The sorcerer and his apprentice , 1982, Diabetologia.

[77]  N. J. Patton,et al.  Mechanisms of Nitrosourea-Induced β-Cell Damage: Activation of Poly (ADP-Ribose) Synthetase and Cellular Distribution , 1988, Diabetes.

[78]  S. Lenzen,et al.  INHIBITION OF GLUCOKINASE AND HEXOKINASE FROM PANCREATIC B-CELLS AND LIVER BY ALLOXAN, ALLOXANTIN, DIALURIC ACID, AND t-BUTYLHYDROPEROXIDE , 1991 .

[79]  R. Heikkila,et al.  Protection against alloxan-induced diabetes by various urea derivatives: relationship between protective effects and reactivity with the hydroxyl radical. , 1979, The Journal of pharmacology and experimental therapeutics.

[80]  S. Lenzen,et al.  Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition , 1988, British journal of pharmacology.

[81]  S. Lenzen,et al.  Relation Between Antioxidant Enzyme Gene Expression and Antioxidative Defense Status of Insulin-Producing Cells , 1997, Diabetes.

[82]  N. Rakieten Studies on the diabetogenic action of streptozotocin , 1963 .

[83]  F. Bedoya,et al.  N-Monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets , 1996, Experientia.

[84]  A. Preston Modification of streptozotocin-induced diabetes by protective agents , 1985 .

[85]  W. Cowden,et al.  Auto-oxidation of dialuric acid, divicine and isouramil. Superoxide dependent and independent mechanisms. , 1989, Biochemical pharmacology.

[86]  L. Hammarström,et al.  On the accumulation of alloxan in the pancreatic beta-cells. , 1967, Diabetologia.

[87]  H. Okamoto,et al.  Streptozotocin and alloxan induce DNA strand breaks and poly(ADP–ribose) synthetase in pancreatic islets , 1981, Nature.

[88]  S. Snyder,et al.  Poly (ADP-ribose) polymerase, nitric oxide and cell death. , 1999, Trends in pharmacological sciences.

[89]  S. Lenzen,et al.  Relative importance of cellular uptake and reactive oxygen species for the toxicity of alloxan and dialuric acid to insulin-producing cells. , 2006, Free radical biology & medicine.

[90]  T. Ochiya,et al.  Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[91]  H. Najafi,et al.  Identification of Glucokinase as an Alloxan-Sensitive Glucose Sensor of the Pancreatic β-Cell , 1986, Diabetes.

[92]  S. Lenzen,et al.  Glucokinase in pancreatic B-cells and its inhibition by alloxan. , 1987, Acta endocrinologica.

[93]  S. Lenzen,et al.  Signal recognition by pancreatic B-cells. , 1988, Biochemical pharmacology.

[94]  D. Hearse,et al.  Autoradiographic study of the distribution and cellular uptake of (14C)-streptozotocin in the rat , 1976, Diabetologia.

[95]  R. Lorentzon,et al.  Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro. , 1983, Endocrinology.

[96]  S. Ledoux,et al.  Effects of streptozotocin on a clonal isolate of rat insulinoma cells. , 1984, Biochimica et biophysica acta.